FDA has accepted a supplemental New Drug Application and granted priority review for Keytruda (pembrolizumab), an anti-PD-1 therapy.
In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.
